X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NR082
Therapeutic Area: Ophthalmology Product Name: NFS-01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
NR082, a novel recombinant adeno-associated viral serotype 2 containing a codon-optimized of ND4 gene under the control of the cytomegalovirus promoter and enhancer, is a novel ophthalmic injection that is being developed for the treatment of LHON in ND4 mutations.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: OT-101
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 10, 2020
Details:
Ocumension's IPO marks a significant milestone in its journey to become China's leading ophthalmology platform. Company intent to use these funds to continue expanding its portfolio with innovative new drug assets.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
